Advertisement
Finance
Subscribe to Finance

The Lead

Perrigo Out-Licenses Preclinical Assets to Imago Pharmaceuticals

September 29, 2014 2:10 pm | News | Comments

Perrigo Company has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals.     

New EU Trade Chief Seeks Reset in US Trade Talks

September 29, 2014 1:29 pm | by JUERGEN BAETZ, Associated Press | News | Comments

Acknowledging strong public skepticism in Europe over free trade talks with the U.S., the...

Daiichi Sankyo to Acquire Ambit Biosciences

September 29, 2014 10:15 am | News | Comments

Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered...

Amag Pharma to Spend $675M on Lumara Health

September 29, 2014 10:03 am | News | Comments

The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $...

View Sample

FREE Email Newsletter

Exelixis Shares Soar on Skin Cancer Study Results

September 29, 2014 9:54 am | News | Comments

Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.          

Inovio Pharma Plans Human Trials of Ebola Vaccine

September 24, 2014 1:27 pm | News | Comments

The company creates DNA-based vaccines and immune therapies, and said its vaccine might be able to address a variety of developing strains of Ebola. Inovio said that it will work with GeneOne Life Science, a company in which Inovio owns a minority stake.

Valeant Pharma Expects Third Quarter Revenue to Top Forecasts

September 24, 2014 1:07 pm | by The Associated Press | News | Comments

Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.      

Advertisement

Analyst: GSK's $490M Fine to Spark Pharma Strategy Shift in Emerging Markets

September 24, 2014 11:21 am | News | Comments

The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.           

Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood Blindness

September 24, 2014 8:32 am | News | Comments

Genzyme, a Sanofi company, today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness.

Baxter and Merrimack Pharmaceuticals to Develop and Commercialize Cancer Compound

September 24, 2014 8:13 am | News | Comments

Baxter International and Merrimack Pharmaceuticals have announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.''    

Acorda Therapeutics to Acquire Civitas Therapeutics

September 24, 2014 8:05 am | News | Comments

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease (PD).

UPS Survey: Time to Act on Untapped Opportunites in Healthcare Industry

September 23, 2014 2:48 pm | News | Comments

An environment of increasing risks, complex regulations and continuing cost pressures is impeding healthcare executives from moving quickly to seize untapped industry opportunities, according to the 7th annual UPS "Pain in the (Supply) Chain" survey.

Advertisement

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer

September 23, 2014 9:12 am | News | Comments

Navidea Biopharmaceuticals today announced the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund evaluation of Lymphoseek ® (technetium Tc 99m tilmanocept) Injection in women with cervical cancer.

IMS Health Identifies Ten Harbingers of Disruptive Change to Healthcare Systems and Business Models

September 23, 2014 8:43 am | News | Comments

As the global market for drugs surpasses $1 trillion this year, growing payer scrutiny of value for money is just one of the factors that will drive disruptive change in the use of medicines over the next decade, according to a report issued today by the IMS Institute for Healthcare Informatics.

Limits on Overseas Mergers Prompt Renewed Debate

September 23, 2014 8:05 am | by JOSH LEDERMAN, Associated Press; JIM KUHNHENN, Associated Press | News | Comments

The Obama administration's decision to curb the ability of U.S. corporations to skirt taxes by merging with foreign companies kicked off an immediate election-season debate over when and how to tackle the nation's complex corporate tax code.  

Access Pharmaceuticals Announces New Management and New Corporate Name

September 22, 2014 9:01 am | News | Comments

ACCESS Pharmaceuticals has signed an exclusive, global license agreement with Plasma Technologies for the development and commercialization of its proprietary plasma fractionation process. Concurrently, the company announced a new corporate management team and its intention to strategically refocus and rebrand the company as PlasmaTech Biopharmaceuticals.

Advertisement

Lannett Launches Oxycodone Hydrochloride Oral Solution

September 22, 2014 8:36 am | News | Comments

Lannett Company today announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price (AWP) were approximately $43M.

Avalon Ventures and GlaxoSmithKline Launch Two New Companies

September 22, 2014 8:08 am | News | Comments

Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.

Auxilium Pharma Rejects Endo's Takeover Offer

September 22, 2014 8:02 am | News | Comments

Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.    

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

Soligenix Awarded $24.7M NIAID Contract to Develop Heat Stable RiVax Vaccine

September 19, 2014 8:11 am | News | Comments

The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.

Elanco Animal Health, Dow AgroSciences Announce Strategic R&D Agreement

September 18, 2014 9:09 am | News | Comments

Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic R&D agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.

Bayer to Split Off Polymer Division with IPO

September 18, 2014 7:45 am | by The Associated Press | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

Auxilium Pharma Board Adopts Anti-Takeover Plan

September 17, 2014 8:48 am | by The Associated Press | News | Comments

The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.   

EMD Serono and Sutro Biopharma Announce $298M Deal to Develop Antibody Drug Conjugates

September 17, 2014 8:14 am | News | Comments

EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading